Amicus Therapeutics Announced Transfer or Voluntary Withdrawal of Listing

Amicus Therapeutics announced on April 27, 2026, that it has completed its merger and intends to delist its common stock from Nasdaq. The company requested a trading halt on the same day and asked Nasdaq to file a Form 25 for delisting and deregistration. Trading will be suspended on April 28, 2026, and the company plans to file a Form 15 to terminate registration and suspend periodic reporting after the Form 25 becomes effective.

On April 27, 2026, the company notified Nasdaq of the consummation of its merger and its intent to remove its common stock from Nasdaq, requested a trading halt on April 27, and asked Nasdaq to file a Form 25 to delist and deregister the shares. As a result, trading will be suspended on April 28, 2026. Following the Form 25 effectiveness, the company intends to file a Form 15 to terminate registration and suspend periodic reporting.

Original SEC Filing: AMICUS THERAPEUTICS, INC. [ FOLD ] - 8-K - Apr. 27, 2026

Disclaimer

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.